BOLT BIOTHERAPEUTICS
NASDAQ: BOLT (Bolt Biotherapeutics, Inc.)
Kemas kini terakhir: 13 jam lalu6.59
0.23 (3.62%)
| Penutupan Terdahulu | 6.36 |
| Jumlah Dagangan | 249,850 |
| Harga / Jualan (P/S) | 2.37 |
| Harga / Buku (P/B) | 0.970 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -991.41% |
| EPS Cair (TTM) | -33.20 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -76.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 52.79% |
| Nisbah Semasa (MRQ) | 3.13 |
| Aliran Tunai Operasi (OCF TTM) | -57.90 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -34.68 M |
| Pulangan Atas Aset (ROA TTM) | -34.57% |
| Pulangan Atas Ekuiti (ROE TTM) | -83.92% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Bolt Biotherapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | 1.0 |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 2.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | -0.5 |
| Persekitaran Makro | -0.3 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | -0.54 |
|
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.26% |
| % Dimiliki oleh Institusi | 46.17% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Board Of Trustees Of The Leland Stanford Junior University | 30 Jun 2026 | 35,977 |
| Pfizer Inc | 30 Jun 2026 | 31,305 |
| Lynx1 Capital Management Lp | 30 Jun 2026 | 30,800 |
| Nan Fung Group Holdings Ltd | 30 Jun 2026 | 5,000 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| GUJRATHI SHEILA | 6.27 | - | 85,821 | 538,098 |
| Jumlah Keseluruhan Kuantiti Bersih | 85,821 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 538,098 | |||
| Purata Pembelian Keseluruhan ($) | 6.27 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| GUJRATHI SHEILA | Pegawai | 23 Oct 2026 | Diperolehi (+) | 72,766 | 6.27 | 456,243 |
| GUJRATHI SHEILA | Pegawai | 23 Oct 2026 | Diperolehi (+) | 13,055 | 6.27 | 81,855 |
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |